Aegerion Pharmaceuticals, Inc. (AEGR) Presents Data From Phase 3 Extension Study Of JUXTAPID™ (Lomitapide) Capsules In Homozygous Familial Hypercholesterolemia (Hofh) At American Heart Association Scientific Sessions
11/18/2013 12:45:46 PM
CAMBRIDGE, Mass., Nov. 18, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of novel, life-altering therapies for patients with debilitating, often fatal, rare diseases, today presented data from its open-label Phase 3 extension study of JUXTAPID™ (lomitapide) capsules in patients with homozygous familial hypercholesterolemia (HoFH). The data were presented in a poster at the American Heart Association's Scientific Sessions taking place in Dallas.
Help employers find you! Check out all the jobs and post your resume.
comments powered by